IRTCHealthcare · Medical DevicesThe 15 Wall Street analysts covering iRhythm Holdings, Inc. hold a median 12-month price target of $178 — +67.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores iRhythm Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (91): The business earns solid, repeatable profits on what it owns.
Momentum (14): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IRTC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +67.4% from it.
Of the 20 most recent actions, 3 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Oct 2026 | Freedom Capital Markets | Maintains | Buy | $190 |
| 6 Oct 2026 | Wells Fargo | Maintains | Overweight | $168 → $150 |
| 5 Oct 2026 | Needham | Maintains | Buy | $192 → $194 |
| 18 Aug 2026 | Wells Fargo | Maintains | Overweight | $180 → $168 |
| 18 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 10 Aug 2026 | Truist Securities | Maintains | Buy | $160 → $168 |
| 10 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 7 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 7 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $150 → $165 |
| 7 Aug 2026 | Needham | Maintains | Buy | $255 → $192 |
| 7 Aug 2026 | Needham | Maintains | Buy | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $180 → $168 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 23 July 2026 | Stephens & Co. | Initiates | Overweight | $160 |
| 23 July 2026 | Stephens & Co. | Initiates | Overweight | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 16 July 2026 | Truist Securities | Maintains | Buy | $174 → $160 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 22 June 2026 | BTIG | Reiterates | Buy | — |
| 10 June 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IRTC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, iRhythm Holdings, Inc. returned −40.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 28% of US stocks
Cheaper than 5% of US stocks
Cheaper than 1% of US stocks
Higher than 69% of US stocks
Higher than 58% of US stocks
Higher than 85% of US stocks
Higher than 60% of US stocks
Higher than 28% of US stocks
Higher than 36% of US stocks
Higher than 47% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
iRhythm Holdings, Inc. has a market value of $3.6B and an enterprise value of $3.7B.
Revenue in the twelve months to 30 June 2026: $825.3M. The latest quarter grew 20.1% year on year.
Net income over the same four quarters: −$13.9M, a −1.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.43.
Free cash flow in the twelve months to 30 June 2026: $39.0M.
Trailing P/E: −77.5×; forward P/E: 84.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
iRhythm Holdings, Inc. employs 2,400 people — $344K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own iRhythm Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A PRNewsWire item asks iRhythm Technologies shareholders to contact a law firm to discuss their rights and options, at no cost or obligation. The firm says it would handle any matter on a contingent-fee basis.
Why it matters — IRTC watchers may note the shareholder-focused legal outreach concerning alleged fiduciary-duty breaches referenced in the headline.
iRhythm Holdings, Inc. announced it has completed its previously announced acquisition of VitalConnect, a leader in wearable biosensor technology and ambulatory cardiac monitoring. The acquisition expands iRhythm's cardiac monitoring platform across ambulatory, inpatient, and hospital-to-home care settings.
Why it matters — The completed acquisition broadens iRhythm's cardiac monitoring capabilities and reach across additional care settings, which is significant for investors tracking the company's platform expansion.
iRhythm Holdings, Inc. provided an update on the cybersecurity incident previously disclosed in June 2026. Following the completion of the forensic investigation, the company has begun notifying impacted individuals.
Why it matters — Investors following IRTC will want to monitor the scope and potential repercussions of the cyber incident, including notification of affected individuals and any resulting regulatory or reputational impact.
Zacks Investment Research reports that iRhythm's Q2 momentum, AI-driven predictive care, and deeper EHR integration support growth, while reimbursement pressures persist. The article advises retaining IRTC stock for now.
Why it matters — IRTC watchers would care because the item highlights both the company's key growth drivers and the ongoing reimbursement pressures that continue to affect its outlook.
iRhythm reported stronger Q2 performance, including revenue growth, margin expansion and record free cash flow. However, the company continues to face elevated reimbursement and regulatory risks.
Why it matters — An IRTC watcher would care because the improved financial results strengthen the company's case while persistent reimbursement and regulatory uncertainties remain key risks to monitor.
The 15 Wall Street analysts covering iRhythm Holdings, Inc. have a median 12-month price target of $178, with estimates ranging from $150 to $196. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering iRhythm Holdings, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks iRhythm Holdings, Inc. 71 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, iRhythm Holdings, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +67.4% from the last close, and Ticker Nerd's factor model ranks iRhythm Holdings, Inc. 71 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering iRhythm Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IRTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $150 to $196 over the next 12 months.
iRhythm Holdings, Inc. returned -40.0% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
iRhythm Holdings, Inc. is a digital healthcare company focused on ambulatory cardiac monitoring and arrhythmia detection.
The most recent item we track (PRNewsWire, 13 Oct 2026): "Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?". A PRNewsWire item asks iRhythm Technologies shareholders to contact a law firm to discuss their rights and options, at no cost or obligation. The firm says it would handle any matter on a contingent-fee basis.
iRhythm Holdings, Inc. is a digital healthcare company focused on ambulatory cardiac monitoring and arrhythmia detection. The company develops and commercializes wearable, device-based technology that helps clinicians capture and analyze heart rhythm data outside of the hospital setting. Its product portfolio includes remote ECG monitoring systems and connected software tools that support physician review, patient data collection, and clinical workflow management. iRhythm Holdings serves cardiology, electrophysiology, primary care, and other specialty practices that rely on timely rhythm assessment to guide diagnosis. The company’s platform combines biosensors, cloud-based analytics, and proprietary algorithms to turn long-duration heartbeat data into clinically useful reports. Headquartered in San Francisco, iRhythm Holdings operates in the healthcare technology and medical devices market, where it plays a specialized role in noninvasive cardiac diagnostics.
CEO Mr. Quentin S. Blackford · 2,400 employees · United States · https://www.irhythmtech.com
